Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Gossec, Laure ^a,b   Dougados, Maxime ^c,d   Dixon, William ^e  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PARIS DESCARTES UNIVERSITY   (France)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193398     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2014-000019     Document Type: Review

References (41)

1. Scott DL, Lempp HK. Outcomes associated with early rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res 2006;6:495-508.
2. http://handbook.cochrane.org/chapter-17/17-patient-reported-outcomes.htm (accessed 16 Feb 2015).
3. Kirwan JR, Heiberg T, Hewlett SA. Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003;30:868-72.
4. Kirwan JR, Bartlett SJ, Beaton DE, et al. Updating the OMERACT filter: implications for patient-reported outcomes. J Rheumatol 2014;41:1011-15.
5. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012;64:640-7.
6. Stoffer MA, Smolen JS, Woolf A, et al. Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis 2014;73:902-5.
7. http://www.pcori.org/ (accessed 16 Feb 2015).
8. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
9. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf (accessed 16 Feb 2015).
10. http://www.proqolid.org/ (accessed 16 Feb 2015).
11. http://Olga-QoL.com (accessed 16 Feb 2015).
12. http://oml.eular.org/ (accessed 16 Feb 2015).
13. Kalyoncu U, Dougados M, Daurès JP, et al. Reporting of patientreported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2009;68:183-90.
14. Tugwell P, Boers M. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. J Rheumatol 1993;20:555-6.
15. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
16. Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994;41:86-9.
17. Kirwan JR, Minnock P, Adebajo A, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-7.
18. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ ACR collaborative recommendations. Ann Rheum Dis 2008;67:1360-4.
19. Kirkham JJ, Boers M, Tugwell P, et al. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials 2013;14:324.
20. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritisprogress at OMERACT 7. J Rheumatol 2005;32:2250-6.
21. Ahlmen M, Nordenskiöld U, Archenholtz B, et al. Rheumatology outcomes: the patient's perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology 2005;44:105-10.
22. Carr A, Hewlett S, Hughes R, et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003;30:880-3.
23. Gossec L, Dougados M, Rincheval N, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680-5.
24. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/06/WC500168852.pdf (accessed 16 Feb 2015).
25. Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes 2010;8:89.
26. Boers M, Kirwan JR, Wells G, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745-53.
27. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:506-14.
28. Khan NA, Spencer HJ, Abda E, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012;64:206-14.
29. French T, Hewlett S, Kirwan J, et al. Different wording of the Patient Global Visual Analogue Scale (PG-VAS) affects rheumatoid arthritis patients' scoring and the overall Disease Activity Score (DAS28): a cross-sectional study. Musculoskeletal Care 2013;11: 229-37.
30. Pincus T, Sokka T, Kavanaugh A. Quantitative documentation of benefit/risk of new therapies for rheumatoid arthritis: patient questionnaires as an optimal measure in standard care. Clin Exp Rheumatol 2004;22(5 Suppl 35):S26-33.
31. Castrejón I, Carmona L, Agrinier N, et al. The EULAR Outcome Measures Library: development and an example from a systematic review for systemic lupus erythematous instruments. Clin Exp Rheum 2015, [Epub ahead of print 23 Mar 2015].
32. Wells G, Li T, Maxwell L, et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008;67:260-5.
33. Gossec L, Paternotte S, Aanerud G, et al. Finalisation and validation of the Rheumatoid Arthritis Impact of Disease (RAID) score: a patient-derived composite measure of impact of RA. A EULAR initiative. Ann Rheum Dis 2011;70:935-42.
34. http://www.nihpromis.org/ (accessed 16 Feb 2015).
35. Hewlett S, Cockshott Z, Byron M, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697-702.
36. Nikolaus S, Bode C, Taal E, et al. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2013;65:1128-46.
37. Chauffier K, Salliot C, Berenbaum F, et al. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford) 2012;51:60-8.
38. Brundage M, Blazeby J, Revicki D, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res 2013;22:1161-75.
39. Dures E, Cramp F, Greenwood R, et al. Reliability and sensitivity of the Bristol RA Fatigue Multidimensional Questionnaire (BRAF-MDQ) and BRAF short scales. Rheumatology (Oxford) 2013;52: 1832-9.
40. Sanderson T, Morris M, Calnan M, et al. Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken) 2010;62:647-56.
41. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.